Spots Global Cancer Trial Database for bispecific antibody
Every month we try and update this database with for bispecific antibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | NCT05377658 | Non-small Cell ... | AK104 Albumin-Bound P... Carboplatin | 18 Years - 75 Years | Henan Cancer Hospital | |
| This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 | NCT03292783 | Advanced Solid ... | NOV1501 (ABL001... | 19 Years - | ABL Bio, Inc. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | NCT03540199 | Advanced Kidney... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | NCT05117242 | Non Small Cell ... | Acasunlimab Pembrolizumab | 18 Years - | Genmab | |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | NCT02892123 | HER2-expressing... | ZW25 (Zanidatam... Paclitaxel Capecitabine Vinorelbine Tucatinib Tucatinib | 18 Years - | Jazz Pharmaceuticals | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Expanded Access Program for Epcoritamab | NCT05733650 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High Grade B-ce... Grade 3B Follic... | Epcoritamab | 18 Years - | Genmab | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | NCT05773105 | Advanced Hepato... | Cadonilimab+reg... | 18 Years - 75 Years | Sun Yat-sen University | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| Expanded Access Program for Epcoritamab | NCT05733650 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High Grade B-ce... Grade 3B Follic... | Epcoritamab | 18 Years - | Genmab | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| FS222 First in Human Study in Patients With Advanced Malignancies | NCT04740424 | Advanced Cancer Metastatic Canc... | FS222 | 18 Years - | invoX Pharma Limited | |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | NCT05577182 | Advanced Malign... | INCA32459-101 | 18 Years - | Incyte Corporation | |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | NCT05263180 | Advanced Solid ... | EMB-09 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | NCT06215118 | Multiple Myelom... | Elranatamab Iberdomide | 18 Years - | Pfizer | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01466179 | Acute Lymphobla... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | NCT05079282 | Relapsed or Ref... | ONO-4685 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | NCT03540199 | Advanced Kidney... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT06417008 | Non-Squamous No... | HS-20117 Aumolertinib | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| BATs Treatment for Pancreatic Cancer, Phase Ib/II | NCT03269526 | Locally Advance... Metastatic Panc... | EGFR BATs after... | 18 Years - | University of Virginia | |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | NCT02892123 | HER2-expressing... | ZW25 (Zanidatam... Paclitaxel Capecitabine Vinorelbine Tucatinib Tucatinib | 18 Years - | Jazz Pharmaceuticals | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | NCT03484962 | Advanced Liver ... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | NCT05464329 | Diffuse Large B... High-grade B-ce... Transformed B-C... Follicular Lymp... | Mosunetuzumab DHAX ICE | 18 Years - | Washington University School of Medicine | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | NCT04649359 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | Pfizer | |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | NCT05955508 | Smoldering Mult... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | NCT06310473 | Gastric Cancer Esophagogastric... | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | NCT05932290 | Multiple Myelom... | Elranatamab Standard of car... | 18 Years - | Pfizer | |
| Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer | NCT00860860 | Colorectal Neop... | TF2 IMP-288 labeled... | 18 Years - | Radboud University Medical Center | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma | NCT06359067 | Multiple Myelom... | Treated by bisp... Not treated by ... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | NCT03501056 | Advanced Lung C... | Activated CIK a... Cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | NCT03643276 | Acute Lymphobla... | Blinatumomab Bortezomib Cyclophosphamid... Cytarabine Daunorubicin Myocet Dexamethasone Doxorubicin Etoposide Fludarabine Pho... Ifosfamide 6-Mercaptopurin... Methotrexate Pegaspargase Prednisolone Tioguanin Vincristine Vindesine Erwinase | - 17 Years | University Hospital Schleswig-Holstein | |
| A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | NCT03440437 | Advanced Cancer Metastatic Canc... Squamous Cell C... | FS118 Paclitaxel | 18 Years - | invoX Pharma Limited | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | NCT06416930 | Pleural Mesothe... | Cadonilimab Com... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | NCT05930665 | Pleural Mesothe... | Cadonilimab+Bev... | 18 Years - | Sun Yat-sen University | |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | NCT04466891 | HER2-amplified ... | ZW25 (Zanidatam... | 18 Years - | Jazz Pharmaceuticals | |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | NCT05955508 | Smoldering Mult... | Linvoseltamab | 18 Years - | Regeneron Pharmaceuticals | |
| A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | NCT03821233 | HER2-expressing... | ZW49 | 18 Years - | Zymeworks BC Inc. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | NCT03484962 | Advanced Liver ... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | NCT06057402 | Multiple Myelom... | Elranatamab | 18 Years - | Pfizer | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | NCT03524261 | Advanced Breast... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | NCT05377658 | Non-small Cell ... | AK104 Albumin-Bound P... Carboplatin | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | NCT05675449 | Multiple Myelom... | Elranatamab Carfilzomib Maplirpacept | 18 Years - | Pfizer | |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | NCT05152147 | Gastric Neoplas... Gastroesophagea... Esophageal Aden... | Zanidatamab Tislelizumab Trastuzumab Capecitabine Oxaliplatin Cisplatin 5-Fluorouracil | 18 Years - | Jazz Pharmaceuticals | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | NCT05117242 | Non Small Cell ... | Acasunlimab Pembrolizumab | 18 Years - | Genmab | |
| Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors | NCT05101109 | Advanced Solid ... | ABL501 | 18 Years - | ABL Bio, Inc. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | NCT03509298 | Advanced Pancre... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | NCT05775159 | Hepatocellular ... Biliary Tract C... | Volrustomig Bevacizumab Lenvatinib Rilvegostomig Gemcitabine Cisplatin | 18 Years - | AstraZeneca | |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | NCT05263180 | Advanced Solid ... | EMB-09 | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | NCT03524274 | Advanced Colore... | Activated CIK a... Cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01207388 | B-cell Acute Ly... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | NCT05410418 | Lymphoma, Folli... Follicular Lymp... | Mosunetuzumab Polatuzumab ved... | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
